A randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy

Manchester University NHS Foundation Trust0 sites152 target enrollmentSeptember 7, 2020

Overview

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37137675/ (added 04/05/2023)

Registry

who.int

Start Date

September 7, 2020

End Date

April 30, 2024

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Written informed consent given
•2\. Aged between 18 and 75 years inclusive (Updated 07/11/2023: previously between 18 and 70 years inclusive)
•3\. Hypertrophic cardiomyopathy (HCM), as defined by the European Society of Cardiology HCM guidelines as: a wall thickness \> \= 15 mm in one or more LV myocardial segments that is not explained solely by loading conditions”. The same definition is applied to first\-degree relatives of patients with HCM i.e. all participants are required to have a LV wall thickness \> \= 15 mm. Wall thickness is as measured on the most recent cardiovascular magnetic resonance (CMR) scan performed prior to the baseline visit. If CMR has not been performed previously, wall thickness measurement should be taken from the most recent echocardiogram performed prior to the baseline visit. (It is recognised that in the European Society of Cardiology guidelines a clinical diagnosis of HCM in first\-degree relatives requires a wall thickness that is less than this value, however \> \= 15 mm is applied here in order to ensure that all participants have an unequivocal phenotype).
•4\. New York Heart Association class I, II or III at the most recent clinical assessment performed prior to the baseline visit

•1\. Previous or planned septal reduction therapy
•2\. Previously documented myocardial infarction or severe coronary artery disease
•3\. Uncontrolled hypertension, defined as a systolic blood pressure of \>180 mmHg or diastolic blood pressure of \>100 mmHg at visit 1
•4\. Known LV EF \<50%, as measured on the most recent CMR scan performed prior to the baseline visit. If CMR has not been performed previously, the most recent echocardiogram performed prior to the baseline visit should be used.
•5\. Previously documented persistent atrial fibrillation
•6\. Anaemia, defined as haemoglobin being below the local site normal reference range, at visit 1
•7\. Iron deficiency, defined as serum iron being below the local site normal reference range, at visit 1
•8\. Copper deficiency, defined as serum copper being below the normal reference range, at visit 1
•9\. Pacemaker or implantable cardioverter\-defibrillator
•10\. Known severe valvular heart disease, as demonstrated on the most recent heart imaging performed prior to the baseline visit